SEC Form 4 · accession 0001363213-16-000066
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Friedhelm Blobel
Officer — President & CEO · Director
Period of report
Mar 15, 2016
Accepted (ET)
Mar 17, 2016 · 12:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1,F2 | $9.12 | Mar 15, 2016 | A | 11,243 | A | — | Mar 15, 2026 | Common Stock | 11,243 | 11,243 | D |
| Non-Qualified Stock Option (right to buy)F1,F2 | $9.12 | Mar 15, 2016 | A | 128,757 | A | — | Mar 15, 2026 | Common Stock | 128,757 | 128,757 | D |
| Restricted Stock UnitF1,F3,F4 | — | Mar 15, 2016 | A | 20,000 | A | — | — | Common Stock | 20,000 | 343,500 | D |
Explanation of responses
- F1Granted under the Issuer's 2015 Equity Incentive Plan.
- F225% of such shares vest one year from the date of grant and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.
- F3Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- F4Vesting for such RSUs will occur 25% on March 15, 2017, 25% on March 15, 2018, 25% on March 15, 2019, and 25% on March 15, 2020, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.